Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09LOZ
|
|||
| Former ID |
DIB002154
|
|||
| Drug Name |
TTAC-0001
|
|||
| Synonyms |
VEGFR-2 antibody (cancer), PharmAbcine
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1] | |
| Company |
PharmAbcine
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03856099) TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab. U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.